Category Archives: Transhuman News

Studies in worms, flies, rodents, and monkeys have demonstrated that diets that severely restrict total calorie intake, while providing all the essential nutrients, extend average lifespan.

The research shows that in all these organisms, food shortages trigger physiological changes that promote longevity and delay the onset of age-related disease.

Calorie-restricted diets in humans, which involve reducing average calorie intake by around a third, may also extend human lifespan, though hard evidence is currently lacking.

Animal studies have revealed that timing of calorie restriction can have an effect due to the circadian system, which controls daily cycles of physiology, metabolism, and behaviors such as eating. This has also been linked to aging.

This led researchers at the University of Texas (UT) Southwestern Medical Center in Dallas, TX, to investigate whether the timing of meals contributes to the life-extending effects of calorie restriction.

Numerous studies have shown that calorie restriction increases the average lifespan of mice. But most of this research has involved scientists feeding calorie-restricted diets to laboratory mice during the day.

Unlike humans, mice are nocturnal, which means they have evolved to feed at night.

So for their study, the scientists used automatic feeders to ensure that some of the mice ate only during the night.

To determine whether the timing of meals had an effect on lifespan independently of calorie restriction and fasting they split the animals into 6 groups.

In one group, which served as a control, the animals could eat ad libitum (as much as they wanted, whenever they wanted).

The remaining 5 groups ate calorie-restricted diets (3040% fewer calories) with the same total calorie intake but different feeding schedules.

Control mice that ate ad libitum had a median lifespan of 800 days, whereas mice on a calorie-restricted diet with food available around the clock lived 875 days, or 10% longer.

Mice on the calorie-restricted diet that ate only during the day (the inactive phase of their circadian cycle) and fasted for 12 hours overnight lived 959 days. In other words, they lived almost 20% longer than the controls.

But calorie-restricted mice that only ate during their active phase, then fasted for the remaining 12 hours, lived the longest. These animals clocked up an average 1,068 days of lifespan, which was nearly 35% longer than the control animals.

The scientists have reported their findings in Science.

We have discovered a new facet to caloric restriction that dramatically extends lifespan in our lab animals, says senior author Dr. Joseph Takahashi, Howard Hughes Medical Institute Investigator and chair of neuroscience at UT Southwestern Medical Center.

If these findings hold true in people, we might want to rethink whether we really want that midnight snack, he adds.

They also found that calorie-restricted diets improved the animals regulation of glucose levels and insulin sensitivity, but the improvements were greatest for mice that ate only at night (their active phase).

This suggests that the mice were healthier and aged more slowly, Dr. Takahashi told Medical News Today.

The researchers found that, in all the mice, aging increased the activity of genes involved in inflammation and decreased the activity of genes involved in metabolism and circadian rhythms.

Calorie restriction slowed down these age-related changes, but mice that only ate a night reaped the greatest benefits.

Since aging can be considered a progressive ramping up of inflammation, [calorie restriction] is also delaying this age-related increase in inflammation, which is also consistent with delaying the aging process, said Dr. Takahashi.

The authors note some limitations of their study.

In particular, they write that sleep disruption in the mice that ate during the day (during their inactive phase) may have contributed to their shorter lifespan.

In addition, all the mice in the study were male. The authors write that in females, ovarian hormones may provide some protection against disruptions in circadian rhythms.

As with all research that involves animal models, the study may not translate well to humans.

If the findings do apply to humans, which have the opposite active phase to mice, the scientists suggest that eating early in the evening is best for healthy aging.

One day it may even be possible to develop drugs that target circadian genes or the proteins that they make, in order to mimic the anti-aging benefits of eating only during the active phase.

[W]e are working on this idea and searching for drugs that can enhance circadian alignment, said Dr. Takahashi. Fingers crossed!

Eating late at night interferes with the bodys ability to keep blood sugar levels within a healthy range.

A recent study found this was particularly true for people with a particular variation of the gene for the melatonin receptor.

Melatonin is a hormone that helps to govern the sleep-wake cycle. As its levels increase in the evening, this not only triggers sleepiness but also impairs insulin secretion.

As a result, the body has more difficulty controlling blood sugar levels after meals close to bedtime.

Since many people opt for carbohydrate-rich snacks in late evenings, such as chips, cookies, candy, or popcorn, these snacks are more likely to impair blood sugar control and increase ones risk for prediabetes and diabetes, said Mariam Eid, R.D., L.D., a dietitian and founder of A Happy AOneC, which advises teens and young adults recently diagnosed with prediabetes.

Therefore, consuming carbohydrate-rich meals and snacks earlier in the day promotes better blood sugar balance and supports the prevention of prediabetes and diabetes, she told MNT.

The rest is here:
Eating earlier in the evening may have anti-aging benefits - Medical News Today

Once upon a time, I had a pretty awkward and comical date in Santa Monica. I was new-ish to Los Angeles and decided to try out a dating site that was famous for its robust matching algorithms. However, on this particular evening on Pico Boulevard, their matching science was, well, not so robust.

I probably should have known something was awry when the handsome maitre d' wished me "good luck" in a distinct, you're-gonna-need-it kind of tone before taking me to the table where my date was already seated.

In lieu of a warm salutation, my date stood up, scanned me from toes to head (yes, in that particular order), and proclaimed with some audible disappointment, "You're taller than yourdating appprofile said." I replied, "It's nice to meet you too" like any gracious Southern lady would, and proceeded to sit my tall self down. (I'm actually a not-so-tall 5-feet-6-inches, but as my dating profile clearly stated, "I like to wear heels," so you know, do the math.)

The rest of that date could inspire a Saturday Night Live skit, but allow me to cut to the nutrition-relevant chase (since this articleisabout nutrition principles and foodstuffs for a long and healthy life, I promise).

Originally posted here:
You Have Control Over Your Healthspan: A PhD's Go-To Nutrients For Longevity - mindbodygreen.com

Anderson, South Carolina--(Newsfile Corp. - May 18, 2022) - JZZ Technologies Inc. (OTC Pink: JZZI), a diversified technology company focused on digital media and strategic biotechnology acquisitions related to human life extension including human longevity ("JZZ" or the "Company"), is entering into a working relationship with North Brunswick, New Jersey-based DataBoss Inc. ("DataBoss") which is creating relationships with other anticipated entities to validate and enhance its proprietary marketing database of seniors for the purpose of licensing portions of the database to a number of Big Tech companies which are looking to expand their audience reach.

JZZ Technologies, Inc., through its subsidiary Active Lifestyle, has been validating the marketing value of its database of over 35 million seniors. DataBoss has advised JZZ that it has independently valued the database at more than $3 per individual record.

DataBoss, along with other entities with which it is creating relationships, will be assisting JZZ in licensing targeted portions of the database in blocks of several hundred thousand records per agreement to Big Tech companies over the coming quarters. JZZ anticipates that it will be generating revenues of approximately $1 million per month from the licensing agreements. As the database continues to be validated and additional seniors are added, JZZ anticipates substantial revenue growth generated from future licensing agreements.

DataBoss, a leading data and technology company, was founded by Neel Sawant who serves its current president and CEO.

Neel Sawant has over 30-years of International executive IT leadership experience. His expertise lies in identifying innovative, next generation products and solutions and undervalued companies with strategic synergies that can be leveraged for growth in a multi-billion-dollar market. His expertise lies in effectively combining culturally diverse subsidiaries and acquisitions with excellent business processes and strategy development skills.

Story continues

Mr. Sawant's approach is client centric, with the ability to initiate and grow profitable alliances with global vendors and suppliers. By applying this approach, he has successfully developed and sold a rollup corporation (Sii Group) which operated internationally. He presently focuses on M&A and helping companies list with major exchanges, such as at NASDAQ, which companies have an aggregate market cap which exceeds $10 billion. Companies that Mr. Sawant has been engaged with include AmpliTech Group. Inc, Coeptis Therapeutics, CB Scientific Inc., Gourmet Provisions International, Quantum Kore, Xeriant Aerospace, BlockQuarry, TGI Power, Ealixir Inc. and Shubh Network, among others.

Charles Cardona, JZZ's CEO, stated, "JZZ expects to announce new, significant gains in revenues, new strategic partnerships and new products in the coming months resulting from our relationship with DataBoss and Big Tech partners. We're also working on a number of investment initiatives to support our anticipated growth."

Neel Sawant, CEO of DataBoss, commented, "I am excited at the prospect of DataBoss helping monetize the proprietary ActiveLifestyle Media database owned by JZZ Technologies. I am confident we can maximize its values and immediately create new products for a broad range of companies. With our shared capabilities, I believe JZZ's database would help Big Tech companies increase their outreach to new clients."

About DataBoss Inc.

DataBoss Inc., with its unique combination of data-driven decision systems and experienced experts, identifies and facilitates investments in high-potential profit oriented yet responsible companies that provide value to society through sustainable technologies with applications in cleantech, health tech, and other emerging technologies. For more information, please visit Databoss.network.

About JZZ Technologies, Inc.

JZZ Technologies, Inc. is a diversified technology company engaged in the following three distinct business sectors: (i) its digital media business which includes online media and apps (activelifestylemedia.com), content creation, and digital marketing, targeted to active adults 55+, (ii) strategic biotechnology and bioscience related to Human Life Extension and (iii) Human Longevity that can be immediately leveraged to support improved quality of life for the senior population. For more information, please visit http://www.jzztechnologies.com.

Press Contact:JZZ Technologies, Inc.Charles Cardona, CEOccardona@jzztechnologies.com

DISCLAIMER and FORWARD-LOOKING STATEMENTS

Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities and Exchange Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, and such Forward-Looking Statements are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainties. All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to the viability of the Company's business plans, the effect of acquisitions on our profitability, the effectiveness, profitability, and the marketability of the Company's products; the Company's ability to protect its proprietary information; general economic and business conditions; and the volatility of the Company's operating results and financial condition. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates, and projections about the Company and the industry. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances or to changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, management cannot assure the public that their expectations will turn out to be correct. Investors are cautioned that actual results may differ materially from the anticipated results.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/124442

See original here:
JZZ Technologies, Inc. Receives Significant Increase in Valuation of Its Proprietary Database of over 35 Million Seniors - Yahoo Finance

BERLIN, GERMANY / ACCESSWIRE / May 19, 2022 / The Forever Healthy Foundation is pleased to announce the worlds first Rejuvenation Startup Summit will be held October 14-15, 2022 in Berlin. The Rejuvenation Startup Summit is a vibrant networking event for rejuvenation startups, longevity investors, and translational researchers, and aims to accelerate the development of the rejuvenation biotech industry.

Startups will be able to connect with investors in the longevity space, present their approach, and get them interested in their work. Investors can meet the most promising rejuvenation startups from all over the world and get in touch with them straight away. Researchers with a startup itch can learn how to successfully break out of the lab and found or join a rejuvenation startup.

The summit brings together all those working on therapies that aim to vastly extend the healthy human lifespan. In addition to an exciting range of keynote speeches, presentations, and panels, the summit features an all-day startup forum for easy networking. Starting midday on Friday and finishing off on Saturday night with a big party, it offers ample opportunity to connect, learn and network with the most relevant players in the field.

The Rejuvenation Startup Summit is not only open to startups, investors, and translational scientists all interested members of the broader longevity movement, scientists from related fields, aspiring students, and the general media are welcome.

Learn more at: https://forever-healthy.org/summit

About Forever Healthy

Forever Healthy is Michael Greves humanitarian initiative with the mission of enabling people to vastly extend their healthy lifespan. Forever Healthys projects include evaluation of new rejuvenation therapies, evidenced-based curation of the worlds cutting-edge medical knowledge, funding translational research on the root causes of aging, and hosting the annual Undoing Aging Conference and the Rejuvenation Startup Summit. Greves venture capital firm, Kizoo, which provides mentoring, seed and follow-on financing for rejuvenation biotech startups, is also part of the initiative. To date, Kizoo has funded fourteen startups turning research on the root causes of aging into therapies for human application.

Learn more at https://www.forever-healthy.org

Media Contact for Forever Healthy

Frank Schueler, Chief Operating Officer[emailprotected]

SOURCE: Forever Healthy Foundation gGmbH

View source version on accesswire.com: https://www.accesswire.com/702009/Rejuvenation-Startup-Summit-premieres-October-14-15-2022-in-Berlin

View post:
Rejuvenation Startup Summit premieres October, 14-15, 2022 in Berlin - Digital Journal

Concept of a healthy female reproductive system.

The field of female reproductive longevity and inequality is getting more and more attention. In fact, it is one of the hottest areas of the emerging longevity biotechnology industry, and every venture firm in the field is either investing, incubating, or looking for projects in this area. Companies like BOLD Capital, Future Ventures, LongeVC, and iconic biotechnology investors including Bob Nelsen and Christian Angermayer, are all active and significant partners in this area of science. While females generally live longer than men, their reproductive period is limitedsomething that is often overlooked. A females peak reproductive years are between the late teens and late 20s. Fertility starts to decline by age 30, and this decline becomes more rapid once women reach the mid-30s. By 45, fertility declines so much that getting pregnant naturally is unlikely for most women. Likewise, women begin life with a fixed number of eggs in their ovaries, usually around one million. This number decreases as women age. Ovaries age faster than the rest of a womans bodyan understudied phenomenon of a neglected organ. None of us would be here without them. Yet surprisingly little is known about the avocado-shaped organ thats nestled inside half of all humans.

Functional decline in female fertility with age

The ovaries also influence a womans overall health and well-being. This includes how they age, since this organ tends to lose its function with age faster than any other tissue. This is called asynchronous aging, and its one reason why a womans fertility declines, and menopause strikes, while they are still relatively young.

In one of my previous articles, I wrote about Gameto, a biotechnology company that is translating the impact of ovarian aging to develop solutions to improve fertility and stop the impact of menopause on female health. Gametos co-founder and CEO Dina Radenkovic told me about her intention to redefine the narrative around female reproductive longevity and making it more around health and longevity. Gameto is building a platform for ovarian therapeutics to address menopause and improve assisted fertility. Dina told me she hopes it will make women suffer fewer health problems in their later lives. Neglecting the ovariesexcept for their crucial role in IVF treatmentshas been part of a general disregard for many aspects of womens health in the biomedical world.

What surprises me is this: If overall life expectancy is increasing, and it has consistently over the past decade, then shouldnt there be more focus on extending female reproductive life too? Without extending female reproductive life, we are worsening gender inequality in society.

Just two years ago, Nature published a major study out of Stanford University on the variability in rates of cellular aging in 17 major organs. These included the heart, kidney, and spleenbut not the ovaries, despite it being #1 among organs that rapidly age and are known to influence cellular aging in the rest of the body upon their decline.

Luckily, tides are turning, and female reproductive longevity and inequality are rapidly turning into the hottest research areas in longevity science and investment themes in longevity venture capital.

The official headshot of Maryanna Sayenko, co-founder of Future Ventures

I think womens reproductive longevity is becoming an interesting investment sector because its at the nexus of several important trends. Research in this space is finally getting the recognition and influx of talent that it so desperately needs, thanks in large part to efforts of people like Jennifer Garrison who have been championing the needs of the field. Second, investors are recognizing that addressing longevity without attending to womens reproductive longevity is a laughably incomplete picture. Finally, in the last few years incredible entrepreneurs are taking the risk and entering the space with scientifically credible companies, says Maryanna Saenko, a celebrity venture capitalist who co-pilots Future Ventures together with Steve Jurvetson. Saenko and Jurvetson recently backed Gameto and Cambrian Biosciences.

Dr. Daisy Robinton, scientist, model, entrepreneur, founder and CEO of Oviva Therapeutics

In 2020, molecular biologist Daisy Robinton, while working with a biotechnology company to help develop a potential treatment for COVID-19, was told by male colleagues on a Zoom call to consider excluding female mice from testing to avoid unpredictable noise that they believe can obfuscate clear conclusions. Daisya 35 year-old Harvard PhD who is fast becoming a Millennial firebrand on the topic of womens health in TEDx and other talkskept her cool so as not to be labeled difficult, something that women in scienceor any disciplinehave to always be aware of, she said. Taking a deep breath on the Zoom call, she suggested as calmly as possible that including female physiology is critical to developing any therapeutic to be used for a general population.

Dr. James Peyer, founder and CEO, Cambrian Biopharma

In the Spring of 2020 Daisy joined Cambrian Biopharma, which is developing therapeutics to combat the diseases of aging like cancer, heart disease, and Alzheimers disease. She convinced Cambrian co-founder and CEO James Peyer, a biologist and former venture capitalist, to add the aging of ovaries to his companys roster. This led a few months later to the formation of a new company under the Cambrian umbrella co-founded by Daisy called Oviva Therapeutics, powered by $11.5 million in seed fundinga big number for a just-hatched company.

The focus of Daisys company emerged out of her concern and curiosity about her own fertility. In 2018, at age 31, she began to wonder about her own prospects for having children in the futuresince kids now seemed a ways offshe began a deep-dive into issues of fertility. This included what was known, and not known, about the ovaries. I discovered that the ovaries are the first organ that really goes kaput, she said, leading to an accelerated decline in health for womenaffecting bone density, cardiovascular health, sexual function, metabolism, and on and on.

Overall, she noted, cellular aging accelerates an average of six percent after women reach menopause, typically beginning at age 52. And yet we have not put a lot of funding or effort into studying and understanding what this means for our health or how to create solutions to improve the negative consequences, she said.

Teaming up with Harvard molecular biologist and reproductive biology expert David Ppin, Daisy learned that a hormone produced by the ovaries called Anti-Mullerian Hormone (AMH) might be used to extend the functional life of the ovaries. Normally, AMH is used in IVF to measure the fertility of a patient. Ppin was experimenting with it to see if it would slow the progression of ovarian cancer.

Thats when he noticed that flooding ovaries with AMH also suppresses a process known as folliculogenesis. This is a process where some of the immatureor primordial folliclesare recruited for maturation, explained Daisy. Each month of an adult womans reproductive cycle, a group of roughly 1,000 follicles will mature, ultimately leading to ovulation of a single egg from just one follicle, the dominant follicle. The remaining follicles then die and wither away. This process eventually leads to a depletion of most of a womans follicles and the subsequent triggering of menopause. Using AMH to limit folliculogenesis preserves the possibility in the future that the follicles which women are born with and slowly lose over time do not get fully depleted, said Daisy.

We stumbled on this accidently, said Ppin. The result astonished us. When we added AMH, almost all of the immature follicles stopped growing, meaning the ovulation process largely froze in place, thus preserving the ovaries ability to produce mature eggs at a later date.

Harvard pediatric surgeon Patricia Donohoe, one of the great pioneers of reproductive medicine, also has worked closely with Ppin and is a co-founder and key advisor to Oviva and to Daisy. Ppin and Donoahoe developed a bio-engineered version of the naturally occurring AMH hormone. Pre-clinical data indicate that this bio-engineered AMH can protect the immature follicles during chemotherapy treatment, and potentially be used to improve IVF protocols by increasing the yield of viable eggs by 2-3x, a huge deal for women over the age 35.

The bioengineered form of AMH remains experimental, with the company running pre-clinical trials in mice and non-human primates. It is possible this will not succeed, said Daisy, most drug candidates dont, even those that reach human clinical trials. If this happens, she added, Oviva is poised to pivot to develop alternative treatments that would extend ovarian function and ultimately female healthspan.

Im excited about getting support and funding for studying the ovaries, said Daisy. Its a watershed moment in the history of womens health. She also welcomes others to join in.

To understand this field a bit better, I recently chatted about this topic with Daisy.

1. Female reproductive longevity and inequality seem to be a very hot topic. Why now? In your opinion, what triggered this sudden interest from the VCs?

Dr. Daisy Robinton, founder and CEO, Oviva Therapeutics

There has been a growing wave of interest in womens health over the last few years. In some ways COVID highlighted this in a somewhat backwards way. Early on there were statistics suggesting that more men were dying from COVID19 infection than women. This spurred an influx of funding to study female physiology to better understand why and potentially leverage these mechanisms to help men. Because we have historically overlooked females in biomedical research and clinical development, there is so much we dont know.

I think women are being more vocal about their needs, and an increase of women in power or positions of authority to help drive this change. And - there has also been a growing recognition that women have a lot of economic power behind them and the market for womens health is huge. Menopause alone has a market size of 14.7 billion and is growing. The US fertility market alone is $8 billion. And this doesnt even touch the various indications women suffer from that have little to no resources - things that I know patients would pay an arm and a leg to feel better from (endometriosis, PCOS, etc).

And then theres Roe v Wade, which of course is more immediate but brings into stark urgency the threat to womens health, reproductive freedoms and agency. This is a flashpoint and I am both furious and passionate about helping drive change so that females have more opportunities to live healthy, vibrant, resilient lives, so that we can feel and experience agency throughout our lives no matter our age.

2. Can you shine some light on how Oviva approaches the ovarian longevity challenge?

Our fundamental hypothesis is that ovarian function is inherently linked to healthspan, and by preserving or extending ovarian function we will also extend healthspan. Our first hypothesis that we are working on to address this is that through protecting or preserving the ovarian reserve - and therefore not depleting the ovarian reserve which ultimately triggers menopause and ovarian decline will prevent the ovaries from declining in function. Without the signal from a depleted ovarian reserve to shut down, the ovaries will believe that they should keep working rather than senescing and triggering menopause. The AMH/AMHR2 axis is the earliest known point where we can influence this AMH works by preventing immature (or primordial) follicles, each housing a single egg, from leaving the ovarian reserve. By leveraging this mechanism we aim to prevent the attrition of eggs (and primordial follicles) and thus preserve the ovarian reserve.

3. You share some investors with Gameto, can you please expand on how you are different?

Cambrian is our sole investor we are approaching this goal through the lens of longevity and with the hypothesis that extending ovarian function will significantly impact female health. Additionally, we are developing a candidate targeting the AMH/AMR2 axis which has yet to have any clinical development around it to date and are taking a very focused approach to this. The mechanism is fundamentally different from what Gameto is doing (cellular reprogramming), though the goals are similar. Frankly I think this is actually very important - ultimately what will serve women and patients best is having options to choose from. Much like birth control, different people will want or need distinct methodologies/therapeutics to support their health, so I am thrilled that we have a growing field working towards this goal of ovarian longevity. Gameto is working to reconstitute the ovaries, whereas we are looking to support and preserve the endogenous ovaries.

Also, we decided early on to develop a focused, rigorous program that was built out to thoughtfully de-risk as much as possible and to take us to clinic efficiently and effectively. We are initiating talks with the FDA this year, and this seed funding will take this program to IND submission. We have additional programs in early stages of development (more on that later this year will be tied to our Series A), but we felt strongly that we want to devote our attention to this first program and indication in order to drive it forward effectively without diluting our attention across multiple assets to start. We believe this allows us to take a deeper, more rigorous approach to what we are doing and build from a strong foundation. This focused approach sets us apart from other companies in the space that share our mission and who I hope succeed! and who are working on several things simultaneously. For us this seed round and focused approach - we believe - is the most effective strategy to get to clinic and be successful. Related to this, our candidate is closest to clinic and we are excited to test in humans soon and determine whether this has the potential for our broader vision of extending ovarian function - but one step at a time.

4. What do you see as the major obstacles to achieving ovarian longevity?

There are many fundamental questions about ovarian physiology - and womens health more broadly - that remain unanswered. In order to make a positive impact on ovarian biology we also have to understand the consequences of extending ovarian function (positive and negative) to ensure what were doing is safe in humans and achieving the desired goal, which is ultimately to provide therapeutic options to women that preserve agency over their bodies and reproductive health.

5. In the pharmaceutical industry we usually go after specific diseases. And in longevity biotechnology, most companies try to go after dual-purpose targets that may work in aging and disease. What indications are you targeting?

For our first program we are targeting poor responders to IVF. Similar to the longevity field we view this as an important stepping stone to advance our broader goal of prolonging ovarian function and forestalling the negative consequences that occur as the ovaries decline with age. This first indication (and those to follow, currently confidential) will enable us to establish safety and efficacy (evaluating efficacy and function in humans).

Oviva is one of 19 offspring companies tucked into the Cambrian fold that address certain system-wide triggers of aging. These include using stem cells to regenerate damaged or aging tissue; a treatment that counters the effects of those dwindling telomeres; and yet another that inhibits the formation of fibrotic cells that thicken and cause damage to the lung, uterus and other organs. To learn about longevity biotechnology, Cambrian biosciences, and many other cutting-edge academic and industry projects, consider registering for the 9th annual Aging Research and Drug Discovery conference, 29.08-2.09 in Denmark, hosted by the University of Copenhagen.

The rest is here:
Can We Fix Ovarian Aging? Here Is One Startup Up For The Task! - Forbes

Gut health is vital for one's overall health and quality of life. A new study has shown how it can also directly impact brain and eye function, and boost your longevity

Image: Getty Images)

Eating a healthy, balanced diet is an important part of maintaining good health and helping you feel your best.

The gut microbiota, the body's largest population of microorganisms, are increasingly recognised as an important regulator of host immunity and brain health.

All food is ultimately broken down in the gut to a simple form that can enter the bloodstream and be delivered as nutrients throughout our bodies. This is only possible with a healthy digestive system.

A healthy gut contains healthy bacteria and immune cells that ward off infectious agents like bacteria, viruses and fungi.

A healthy gut also communicates with the brain through nerves and hormones, which helps maintain general health and well-being.

Image:

They can be found in the intestine, and a new study has found they they play a vital role in regulating some of the detrimental effects of ageing, meaning it could be a key to living longer.

It has been known for some time that the population of microbes that we carry around in our gut, collectively called the gut microbiota, is linked to overall health.

From inflammatory bowel diseases, cardiovascular, autoimmune, metabolic and neurodegenerative disorders; our gut microbiome could be the determining factor for disease reduction and longevity.

In a new study, faecal transplants in mice showed a reverse of some of the effects of ageing in both the retina and the brain.

Researchers exchanged the gut microbes among three groups of mice: three months old, designed as "young," 18 months old, designated as "old," and 24 months old mice, classified at "aged." A mouse that is two years old is equivalent to a human who is between 70 and 80 years old.

They then analysed the changes in gut composition to better understand how faecal transplantation affected inflammation on the gut barrier, retina of the eye and the brain, which decline with age partly due to chronic inflammation.

Researchers found transferring "faecal slurries" from aged donors to young mice led to a weakening of the gut lining, which allowed bacterial products to enter the circulation, triggering an inflammatory response in the brain and eyes.

However, the harmful effects were shown to be be reversed by faecal transplants from the young donor mice into older mice.

The team also found specific proteins associated with retinal degeneration were elevated in the young mice who received a faecal transplant from the old donors, further bolstering the claims of how ones gut microbiome can affect longevity.

"Our data support the suggestion that altered gut microbiota in old age contributes to intestinal and systemic inflammation, and so may contribute to driving inflammatory pathologies of aged organs," wrote the study authors.

Image:

Professor Simon Carding, from UEA's Norwich Medical School and head of the Gut Microbes and Health Research Programme at the Quadram Institute, added: "This ground-breaking study provides tantalising evidence for the direct involvement of gut microbes in ageing and the functional decline of brain function and vision and offers a potential solution in the form of gut microbe replacement therapy."

Ways to improve your gut health include:

Read More

Read More

Go here to read the rest:
Boost longevity: Healthy gut can improve brain function and increase lifespan - new study - The Mirror